NO20083895L - Anti-IGF-1R human monoklonalantibody formulering - Google Patents
Anti-IGF-1R human monoklonalantibody formuleringInfo
- Publication number
- NO20083895L NO20083895L NO20083895A NO20083895A NO20083895L NO 20083895 L NO20083895 L NO 20083895L NO 20083895 A NO20083895 A NO 20083895A NO 20083895 A NO20083895 A NO 20083895A NO 20083895 L NO20083895 L NO 20083895L
- Authority
- NO
- Norway
- Prior art keywords
- igf
- human monoclonal
- monoclonal antibody
- antibody formulation
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Sammendrag Foreliggende oppfinnelse angår en humant monoklonalt anti-IGF-1R-antistoff-formulering, fremgangsmåte for fremstilling derav og anvendelse derav. 270 29
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06111848 | 2006-03-28 | ||
PCT/EP2007/052569 WO2007110339A1 (en) | 2006-03-28 | 2007-03-19 | Anti-igf-1r human monoclonal antibody formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20083895L true NO20083895L (no) | 2008-10-24 |
Family
ID=37025222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20083895A NO20083895L (no) | 2006-03-28 | 2008-09-11 | Anti-IGF-1R human monoklonalantibody formulering |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1998806A1 (no) |
JP (1) | JP2009531371A (no) |
KR (1) | KR20080104160A (no) |
CN (1) | CN101410137A (no) |
AR (1) | AR060130A1 (no) |
AU (1) | AU2007229554A1 (no) |
BR (1) | BRPI0709229A2 (no) |
CA (1) | CA2647111A1 (no) |
CL (1) | CL2007000797A1 (no) |
CR (1) | CR10295A (no) |
EC (1) | ECSP088778A (no) |
IL (1) | IL193904A0 (no) |
MA (1) | MA30345B1 (no) |
MX (1) | MX2008012295A (no) |
NO (1) | NO20083895L (no) |
RU (1) | RU2008142359A (no) |
TW (1) | TW200815029A (no) |
WO (1) | WO2007110339A1 (no) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010512356A (ja) * | 2006-12-11 | 2010-04-22 | エフ.ホフマン−ラ ロシュ アーゲー | 非経口aベータ抗体製剤 |
GB0702888D0 (en) * | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
UA96473C2 (ru) * | 2007-03-22 | 2011-11-10 | Имклоун Ллк | Жидкая стойкая композиция, которая содержит антитело imc-а12 |
EP2167127A1 (en) * | 2007-07-10 | 2010-03-31 | F. Hoffmann-Roche AG | Novel formulation |
US20100249384A1 (en) * | 2007-11-29 | 2010-09-30 | Stefan Hepbildikler | Immunoglobulin aggregates |
EP2234600B1 (en) * | 2007-12-21 | 2014-08-20 | F. Hoffmann-La Roche AG | Antibody formulation |
WO2010069858A1 (en) * | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
EP2519262A2 (en) * | 2009-12-29 | 2012-11-07 | F. Hoffmann-La Roche AG | Antibody formulation |
US20130136733A1 (en) * | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
US9220776B2 (en) | 2011-03-31 | 2015-12-29 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments |
CN102363040B (zh) * | 2011-10-21 | 2013-05-01 | 北京锐瑟科技有限公司 | 用于粘膜组织的抗微生物肽制剂 |
SG11201508911PA (en) | 2013-04-29 | 2015-11-27 | Hoffmann La Roche | Human fcrn-binding modified antibodies and methods of use |
CN103505729B (zh) * | 2013-05-24 | 2015-10-28 | 华北制药集团新药研究开发有限责任公司 | 一种稳定的狂犬病毒人源抗体组合制剂 |
CN104707146B (zh) * | 2013-12-16 | 2019-04-16 | 浙江海正药业股份有限公司 | 一种含有阿达木单抗的药物组合物 |
KR20160104636A (ko) | 2014-01-15 | 2016-09-05 | 에프. 호프만-라 로슈 아게 | 단백질 A-결합이 개선된 Fc-영역 변이체 |
US10206878B2 (en) * | 2014-05-28 | 2019-02-19 | Nono Inc. | Lyophilized formulation of TAT-NR2B9C with acetylation scavenger |
TW201628649A (zh) | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | 減少醫藥調配物中微可見顆粒之方法 |
MY180297A (en) | 2015-06-24 | 2020-11-27 | Hoffmann La Roche | Anti-transferrin receptor antibodies with tailored affinity |
AU2016329960A1 (en) * | 2015-09-28 | 2018-04-26 | Jiangsu Hengrui Medicine Co., Ltd. | Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicine |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
RU2753390C1 (ru) | 2015-10-02 | 2021-08-13 | Ф. Хоффманн-Ля Рош Аг | Биспецифические антитела к человеческому cd20/человеческому рецептору трансферрина и способы их применения |
CN106199007B (zh) * | 2016-08-03 | 2017-04-05 | 烟台普罗吉生物科技发展有限公司 | 蛋白保护剂 |
CA3031742A1 (en) | 2016-08-16 | 2018-02-22 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
CN109923411B (zh) | 2016-10-25 | 2022-05-31 | 里珍纳龙药品有限公司 | 用于色谱数据分析的方法和系统 |
SG11201909955XA (en) | 2017-05-02 | 2019-11-28 | Merck Sharp & Dohme | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
CN111201042B (zh) | 2017-09-19 | 2024-05-10 | 里珍纳龙药品有限公司 | 减少粒子形成的方法以及由其形成的组合物 |
JP7566637B2 (ja) | 2018-07-02 | 2024-10-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 混合物からポリペプチドを調製するための複数の疎水性相互作用クロマトグラフィーの使用 |
CN114324882B (zh) * | 2020-10-12 | 2022-12-27 | 广东菲鹏生物有限公司 | 蛋白稳定剂及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL133220A0 (en) * | 1997-06-13 | 2001-03-19 | Genentech Inc | Stabilized antibody formulation |
AP2072A (en) * | 2001-01-05 | 2009-12-10 | Pfizer | Antibodies to insulin-like growth factor I receptor |
JP4317010B2 (ja) * | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ,インコーポレイティド | IgG抗体の安定な凍結乾燥医薬製剤 |
JP4473257B2 (ja) * | 2003-04-02 | 2010-06-02 | エフ.ホフマン−ラ ロシュ アーゲー | インスリン様成長因子i受容体に対する抗体及びその使用 |
ES2609010T3 (es) * | 2003-04-04 | 2017-04-18 | Genentech, Inc. | Formulaciones de anticuerpos y de proteínas a concentración elevada |
AR046071A1 (es) * | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
KR100825156B1 (ko) * | 2003-08-13 | 2008-04-24 | 화이자 프로덕츠 인코포레이티드 | 변형된 인간 igf-ir 항체 |
-
2007
- 2007-03-19 CN CNA2007800114320A patent/CN101410137A/zh active Pending
- 2007-03-19 JP JP2009502016A patent/JP2009531371A/ja active Pending
- 2007-03-19 MX MX2008012295A patent/MX2008012295A/es active IP Right Grant
- 2007-03-19 RU RU2008142359/15A patent/RU2008142359A/ru not_active Application Discontinuation
- 2007-03-19 KR KR1020087023673A patent/KR20080104160A/ko not_active Application Discontinuation
- 2007-03-19 AU AU2007229554A patent/AU2007229554A1/en not_active Abandoned
- 2007-03-19 BR BRPI0709229-6A patent/BRPI0709229A2/pt not_active IP Right Cessation
- 2007-03-19 CA CA002647111A patent/CA2647111A1/en not_active Abandoned
- 2007-03-19 EP EP07727047A patent/EP1998806A1/en not_active Withdrawn
- 2007-03-19 WO PCT/EP2007/052569 patent/WO2007110339A1/en active Application Filing
- 2007-03-26 CL CL2007000797A patent/CL2007000797A1/es unknown
- 2007-03-26 TW TW096110388A patent/TW200815029A/zh unknown
- 2007-03-26 AR ARP070101241A patent/AR060130A1/es not_active Application Discontinuation
-
2008
- 2008-09-04 IL IL193904A patent/IL193904A0/en unknown
- 2008-09-11 NO NO20083895A patent/NO20083895L/no not_active Application Discontinuation
- 2008-09-17 CR CR10295A patent/CR10295A/es not_active Application Discontinuation
- 2008-09-26 EC EC2008008778A patent/ECSP088778A/es unknown
- 2008-10-20 MA MA31308A patent/MA30345B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
RU2008142359A (ru) | 2010-05-10 |
TW200815029A (en) | 2008-04-01 |
MA30345B1 (fr) | 2009-04-01 |
KR20080104160A (ko) | 2008-12-01 |
EP1998806A1 (en) | 2008-12-10 |
AR060130A1 (es) | 2008-05-28 |
AU2007229554A1 (en) | 2007-10-04 |
BRPI0709229A2 (pt) | 2011-06-28 |
CA2647111A1 (en) | 2007-10-04 |
CL2007000797A1 (es) | 2008-01-25 |
IL193904A0 (en) | 2011-08-01 |
MX2008012295A (es) | 2008-10-09 |
ECSP088778A (es) | 2008-10-31 |
CR10295A (es) | 2008-10-06 |
CN101410137A (zh) | 2009-04-15 |
JP2009531371A (ja) | 2009-09-03 |
WO2007110339A1 (en) | 2007-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20083895L (no) | Anti-IGF-1R human monoklonalantibody formulering | |
CY2018013I1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
CY1115932T1 (el) | Σκευασμα αντισωματος | |
NO20081124L (no) | Anti-CD 3 antistoff-formuleringer | |
CY1117563T1 (el) | Αντισωματα κατα her3 και χρησεις αυτων | |
CY1117331T1 (el) | Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων | |
NO20170633A1 (no) | Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff . | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
CY1117124T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
CY1116261T1 (el) | Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων | |
CY1111729T1 (el) | Υπογλωσσιο επικαλυμμενο δισκιο | |
NO20083891L (no) | Anti-5T4 antistoffer og anvendelser derav | |
CY1114926T1 (el) | Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων | |
UY31114A1 (es) | Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos | |
NO20074238L (no) | Fiksert dosering av HER-antistoffer | |
EA201100694A1 (ru) | Антитело к cd38 человека и его применение | |
CR20120310A (es) | Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico | |
TW200716646A (en) | (S)-N-methylnaltrexone | |
NO20076687L (no) | Oral doseringsform | |
CY1109916T1 (el) | Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις | |
NO20083593L (no) | Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse | |
EA200970816A1 (ru) | Новая лекарственная форма | |
MX2013002718A (es) | Composiciones de anticuerpo anti-vegfr-3. | |
NO20091386L (no) | Fenyloksyanilinderivater | |
UA96426C2 (ru) | Выделенное человеческое или гуманизированное антитело, которое специфически связывается с il-13 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |